The treatment of bovine sarcoptic mange (Sarcoptes scabiei var. bovis) using eprinomectin extended-release injection

The efficacy of eprinomectin in an extended-release injection (ERI) formulation was evaluated in cattle harbouring induced infestations of Sarcoptes scabiei var. bovis (sarcoptic mange) in three studies conducted in Germany (two studies) and Austria (one study). A total of 44 cattle were included in the studies, 12 in one study and 16 in each of the other two studies. Approximately eight weeks following initial induced infestation, cattle in each study were formed into replicates of two animals each on the basis of pre-treatment bodyweights. Within replicates the animals were randomly allocated to one of two treatments: ERI vehicle (control) or Eprinomectin 5% (w/v) ERI (1.0 mg eprinomectin/kg). Treatments were administered at 1 mL/50 kg bodyweight by subcutaneous injection in front of the shoulder once on day 0. The number of live mites in skin scrapings was determined prior to treatment and at weekly intervals for eight weeks after treatment. Severity of skin lesions was evaluated and scored when skin scrapings were taken. In all studies, animals were weighed before infestation and again prior to and at 56 days after treatment.     

Comparative evaluation of two ivermectin injectable formulations against psoroptic mange in feedlot cattle

A study was carried out to compare the efficacy of two injectable formulations of ivermectin, Ivomec,(1) Merial (IVM reference) and Ivogell,(2) Intervet (IVM generic) in the treatment of psoroptic mange (Psoroptes ovis) in Charollais feedlot cattle. A total of 22 animals were ranked in order of the severity of mange and allocated to 11 replicates of 2 animals each. Within each replicate, one animal was randomly allocated to IVM reference product treatment (Group 1) and one to IVM generic (Group 2). Animals were treated on Day 0 and on Day 8 at the recommended dosage of 200 microg ivermectin/kg bodyweight. The pharmacokinetics profiles (pK) of both IVM formulations were evaluated in plasma samples taken from 6 cattle randomly chosen per group on Day 0, before treatment, and then at 6, 12, 24 hours and daily from Day 2 to Day 7 after the treatment on Day 0. Additionally, the severity of mange lesions was assessed and mites were counted in skin scrapings on Days 0, 8, 15 and 25. Animals were weighed on Day 0 and 25 and body weight and average daily gains (ADG) were evaluated. No statistical differences were found between the cattle of the two groups in any pK parameters, although the mean IVM plasma concentrations in cattle treated with the IVM reference product were consistently higher than those found in cattle treated with the generic compound. By Day 25, all animals in Group 1 had recovered clinically and parasitologically from psoroptic mange while cattle from Group 2 still had mange lesions and, in two animals, living mites were found in the skin scrapings; these differences were significant (P<0.001). The mean body weight of the two groups was significantly different on Day 25 (P<0.01) when animals in Group 1 weighed 20 kg more than those in Group 2. In conclusion, despite similarities in their pharmacokinetic profiles and formulations, the clinical efficacy of the two injectable formulations of IVM differed significantly in their therapeutic efficacy against psoroptic mange in feedlot cattle up to 25 days after treatment: this difference in response was reflected in an incomplete clinical and parasitological response in Group 2 and a slower growth rate.     

Efficacy of topical administration of eprinomectin for treatment of ear mite infestation in six rabbits

Six rabbits naturally infested with Psoroptes cuniculi were treated topically on the skin at the base of the neck with 0.5 mg kg(-1) of 0.5% pour-on eprinomectin for cattle, twice at 14-day intervals. Efficacy of the drug was based on the disappearance of clinical signs and the absence of live mites for a period of 6 weeks. Clinical improvement was seen within 3 days of the first application; however, complete recovery of clinical signs and elimination of mites in 5/6 rabbits did not occur until the end of the study. No adverse reactions attributable to eprinomectin treatment were observed during the observation period. Results of this trial indicated that eprinomectin was partially effective in the treatment of psoroptic mange in rabbits.     

Efficacy of ivermectin against mange and gastrointestinal nematodes of buffalo (Bubalus bubalis)

The incidence of mange in dairy buffalo in India has increased significantly in recent years. The authors record an outbreak of mange affecting a dairy herd stocking about 30,000 buffalo and 1000 cows. The mange mites were either Sarcoptes scabiei or Psoroptes ovis, or a mixed infestation of both. The morbidity rate was 5-30% varying from group to group, with 100% in a severely affected group. Signs noticed were progressive dermatitis, alopecia, keratinization, skin thickened and wrinkled, intense itching and marked loss of condition often ending in death. Great losses of young animals from mange and gastrointestinal nematodes are very common in dairy herds in India. In view of their economic importance, the activity of ivermectin against naturally occurring mange and parasitic infections of adult buffalo and buffalo calves was determined. Ivermectin was administered by subcutaneous injection (IVOMEC 1% w/v - MSD AGVET) at a dose of 200 mcg kg-1 body weight. The efficacy was ascertained from the disappearance of mites from skin scrapings and the reduction in numbers of worm eggs in the faeces. The results of the treatment were dramatic: the mites disappeared within 2 weeks of the drug being administered in the majority of animals, with marked improvement in skin lesions. Four buffalo which had their entire body surface affected with mange needed a second dose on Day 28 for complete recovery. The effect on the nematodes was equally spectacular, with infections of Neoascaris vitulorum, Trichostrongylidae, Oesophagostomum spp. and Bunostomum being eliminated within 1 week of treatment.     

P-23 Clinical and epidemiological characteristics of 153 cases of Sarcoptic acariosis in dogs

A randomized and controlled field study was performed in canine patients to evaluate the efficacy of selamectin in the treatment of naturally occurring Sarcoptes scabiei and Otodectes cynotis infestations in dogs. A total of 227 dogs from six veterinary practices in South Korea were included. Dogs were randomly assigned to treatment with selamectin or a positive-control product. Selamectin was administered as a unit dose providing a minimum of 6 mg/kg in a topical preparation applied to the skin in a single spot on days 0 and 30 [ S. scabiei ( n =  113) and O. cynotis ( n =  114)]. The presence of parasites was assessed before treatment and at 14, 30 and 60 days after the initiation of treatment. The animals were evaluated clinically at each assessment period. Based on skin scrapings, the efficacy of selamectin against S. scabiei infestations on dogs was >95% by day 30, and 100% by day 60. Against O. cynotis , selamectin eliminated mites in 100% of dogs by day 60. However, clinical signs of pruritus, erythema, scale, and crusted papules did not diminish concomittantly with resolution of S. scabiei in skin scrapings. The positive-control products achieved similar results. Therefore, selamectin was safe and effective against sarcoptic mange and ear mites in dogs.
Funding: Pfizer Animal Health.     

Use of selamectin for the treatment of psoroptic and sarcoptic mite infestation in rabbits

Selamectin, a novel avermectin compound, was evaluated for its efficacy against naturally occurring infestations of Psoroptes cuniculi and Sarcoptes scabiei. A total of 42 New Zealand rabbits with psoroptic mange and 37 Angora rabbits with sarcoptic mange were used in the present study. On day 0, infested rabbits were treated topically with either selamectin at minimum dose of 6 mg kg(-1) (6-18 mg kg(-1) for New Zealand rabbits, n = 31 and 10-12 mg kg(-1) for Angora rabbits, n = 23) or vehicle only (control groups, n = 11 for New Zealand rabbits, n = 14 for Angora rabbits). The efficacy of selamectin was assessed both clinically and parasitologically by the presence or absence of viable mites. Rabbits were scraped for sarcoptic mites on days 7, 14, 28, 42 and 56 and had otoscopeic and/or microscopic examination for the detection of Psoroptes mites on days 7, 14, 42 and 56. Fisher's exact test was used to assess differences between the vehicle and selamectin treatment in the number of rabbits without mites (cure rates) on each assessment date. It was found that significantly fewer selamectin-treated rabbits had mites detected on skin scrapings (for S. scabiei) or otoscopeic and/or microscopic examination (for P. cuniculi) (P < 0.01) than the vehicle group. Results of the present study suggest that selamectin is effective against naturally infestations of P. cuniculi and S. scabiei in rabbits.     

Control of cattle mange in southern africa using ivermectin

Seven trials including 768 cattle were conducted in South Africa and Namibia to evaluate the efficacy of the systemic parasiticide ivermectin when administered subcutaneously at a dose rate of 200 micrograms/kg against sarcoptic (Sarcoptes scabiei var. bovis), chorioptic (Chorioptes bovis) and psoroptic (Psoroptes ovis var. bovis) mange mites. The efficacy of a single treatment against Psoroptes and Sarcoptes was greater than against Chorioptes. There was marked clinical cure in all treated cases with loss of crusts and hair regrowth. The number of cases of psoroptic mange in two large herds, of which 42.4% of 724 animals were clinically affected prior to mass treatment, was reduced by 99.3% following a single subcutaneous treatment with ivermectin; a single animal from which mites were recovered may not have been treated. The apparent prevalence and prospects for control and eradication of cattle mange in South Africa and Namibia are discussed.     

Comparative therapeutic effect of moxidectin,doramectin and ivermectin on psoroptes mites infestation in buffalo (<Emphasis Type="Italic">Bubalus bubalis</Emphasis>)

The aim of the present study was to carry out comparative therapeutic effect of moxidectin pour on, doramectin and ivermectin on psoroptes infestation in buffalo. A total of 318 buffalo in 77 small scale herds suspected to have mange mites were examined clinically and parasitologically. Fifty-three (16.66%) buffalo in 25 herds were recorded to be infested; 51 (16.35%) with psoroptic mites, and two (0.31%) with chorioptic mites. Buffalo with psoroptic mites were randomly allocated into three groups (17 buffalo each). First group was treated with moxidectin pour on at a dose rate of 0.5 mg kg^-1. The second group received doramectin (200 μg kg^-1 twice subcutaneously, 14 days apart). The third group received ivermectin (200 μg kg^-1 twice subcutaneously, 14 days apart). Adjunct to each drug, deltamethrin was applied to the surrounding environment twice at a two week interval. Treatment outcomes of 51 buffalo with psoroptic mites showed that moxidectin pour on and doramectin had a significant higher effect on mite count reduction (MANOVA, P < 0.01; Walks^, Lambda, P < 0.01) and clinical sum scores (MANOVA, P < 0.05; Walks^, Lambda, P < 0.05) compared with injectible ivermectin. On clinical level, the number of clinically recovered buffalo in moxidectin and doramectin treated groups was significantly (P < 0.05) higher than that of ivermectin treated group. The result of the present study indicated that psoroptic mites are the main cause of mange in buffalo in Lower Egypt. This is the first report that describes the effect of moxidectin in buffalo. Moxidectin is a good alternative and easily applied drug for treatment of psoroptes infestation in buffalo.     

Use of doramectin for treatment of sarcoptic mange in five Angora rabbits

The efficacy of administering doramectin after moxidectin treatment, which has previously proved only partially effective, was evaluated in five Angora rabbits naturally infested with Sarcoptes scabiei mange. Evaluations included physical examination for clinical signs of sarcoptic mange and collection of skin scrapings for determination of mites. The rabbits first received two subcutaneous injections, 10 days apart, of moxidectin 1% injectable solution at a dosage of 0.2 mg kg(-1) of bodyweight. Although moxidectin treatment resulted in clinical improvement within 10 days post initial injection, on days 10 and 35 post initial treatment live mites were present in skin scrapings. Administration of doramectin 1% injectable solution using the same route and dosage and at similar intervals to moxidectin led to complete disappearance of signs of scabies and parasitological cure in all rabbits.     

米尔贝肟对自然感染疥螨病犬的治疗效果

为了评价米尔贝肟对临床自然感染疥螨犬的治疗效果,选用自然感染疥螨犬65例,随机选择5条服用伊维菌素,另外60条随机分为3组,分别服用高剂量(2g/kg体重)、中剂量(1g/kg体重)、低剂量(0.5g/kg体重)的米尔贝肟。给药后2、14、28、42d和56d,刮取皮屑,检查螨虫和虫卵,同时观察临床症状。试验结束时米尔贝肟高剂量组、伊维菌素组的无螨虫犬的比例和螨虫的下降率均为100%,临床症状如红疹、结痂、过度角化等现象均消失,所有动物毛发都开始大范围重生;米尔贝肟中、低剂量组结果稍差。米尔贝肟按2g/kg体重剂量,每周1次,连续用药3周,给药对自然感染疥螨病犬有很好的治疗效果。     

Udder cleft dermatitis and sarcoptic mange in a dairy herd

OBJECTIVE: To determine prevalence of udder cleft dermatitis in a dairy herd that was experiencing an outbreak of sarcoptic mange. DESIGN: Clinical survey. ANIMALS: 1,597 Holstein cows and late-gestation heifers. PROCEDURE: Animals were examined for udder cleft dermatitis and for skin lesions consistent with sarcoptic or chorioptic mange. Skin scrapings were collected from 56 cows and examined for ectoparasites. The herd was revisited 1 year later, and prevalences of udder cleft dermatitis and lesions consistent with mange were determined in 506 cows. RESULTS: Of the 1,597 cattle examined, 280 (18%) had udder cleft dermatitis, and 1,397 (87.5%) had lesions consistent with mange. In 43 of 56 (77%) cows, skin scrapings revealed Sarcoptes mites. Udder cleft dermatitis was significantly more common in older than in younger cows. In first-lactation cows, udder cleft dermatitis was less common during the first 4 months of lactation than in the later stages of lactation, but udder cleft dermatitis was identified in cows in all stages of lactation and in cows that were not lactating. The herd was treated with eprinomectin to control mites, and prevalence of lesions consistent with mange 1 year later was only 2.8%. However, prevalence of udder cleft dermatitis was still 12%. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that cows in any stage of lactation and cows that are not lactating can have udder cleft dermatitis but that lesions are more common in older cows. Control of sarcoptic mange was accompanied by a moderate reduction in the prevalence of udder cleft dermatitis but did not eliminate the condition.     

Evaluation of the bioequivalence of two formulations of deltamethrin for treatment of sheep with psoroptic mange

OBJECTIVE: To evaluate efficacy of 2 deltamethrin emulsifiable concentrates that differed on the basis of vehicle (methyl glycol acetate [AMG] or 2-propylene glycol 1-methyl ether acetate [AMP]) for the treatment of sheep with mange. ANIMALS: 30 ewes between 11 months and 7 years old that weighed 16 to 71 kg and were naturally infested with Psoroptes ovis. PROCEDURE: Sheep were randomly allocated into 3 groups (13 sheep in group AMP, 13 sheep in group AMG, and 4 negative-control sheep). Each sheep was dipped twice (10-day interval between dippings) in the assigned formulation. Assessment of efficacy was performed on days 3, 7, 14, 21, 28, 35, 42, 49, 56, and 63 after the first dipping. Efficacy was assessed by determining the number of eggs or live mites on those days, as well as regrowth of wool at the end of the study. RESULTS: Psoroptic mange infestation was maintained in the 4 control sheep throughout the study. We did not detect live Psoroptes mites in scrapings after day 7 (AMP group) or after day 14 (AMG group). No parasites were seen after day 14 in either treatment group. Therefore, efficacy was 100% for both treatment groups from days 14 to 63. CONCLUSIONS AND CLINICAL RELEVANCE: The 2 formulations of deltamethrin were equally able to eradicate Psoroptes infestation of sheep after 2 dippings performed in accordance with the label recommendations.     

Efficacy and safety of selamectin against Sarcoptes scabiei on dogs and Otodectes cynotis on dogs and cats presented as veterinary patients

A series of randomized, controlled and masked field studies was conducted in veterinary patients to evaluate the efficacy of selamectin, a novel avermectin, in the treatment of naturally occurring Sarcoptes scabiei infestations on dogs and Otodectes cynotis infestations on dogs and cats. A total of 342 dogs and 237 cats participated in these studies, which were conducted at 40 veterinary practices in the USA and Europe. Animals were randomly assigned to treatment with selamectin or a positive-control product (existing approved products). Selamectin was administered as a unit dose providing a minimum of 6mgkg(-1) (range: 6-12mgkg(-1)) in a topical preparation applied to the skin in a single spot on day 0 (O. cynotis in cats, n=144), or on days 0 and 30 (O. cynotis and S. scabiei in dogs, n=83 and n=122, respectively). The presence of parasites was assessed before treatment and at 30 days (for all studies) and 60 days (for O. cynotis and S. scabiei dog studies) after first treatment. The animals were also evaluated clinically at each assessment period. Based on skin scrapings, the efficacy of selamectin against S. scabiei infestations on dogs was >95% by day 30, and 100% by day 60. Against O. cynotis, selamectin eliminated mites in 94-100% of cats by day 30, and in 90% of dogs by day 60. The positive-control products achieved similar results. Thus, selamectin was safe and effective against ear mites in dogs and cats and sarcoptic mange in dogs when used in field (veterinary patient) studies in dogs and cats of a wide variety of ages and breeds.     

P‐24 Efficacy of selamectin in canine scabies and ear mite infestation in Korea

A randomized and controlled field study was performed in canine patients to evaluate the efficacy of selamectin in the treatment of naturally occurring Sarcoptes scabiei and Otodectes cynotis infestations in dogs. A total of 227 dogs from six veterinary practices in South Korea were included. Dogs were randomly assigned to treatment with selamectin or a positive‐control product. Selamectin was administered as a unit dose providing a minimum of 6 mg/kg in a topical preparation applied to the skin in a single spot on days 0 and 30 [S. scabiei (n = 113) and O. cynotis (n = 114)]. The presence of parasites was assessed before treatment and at 14, 30 and 60 days after the initiation of treatment. The animals were evaluated clinically at each assessment period. Based on skin scrapings, the efficacy of selamectin against S. scabiei infestations on dogs was >95% by day 30, and 100% by day 60. Against O. cynotis, selamectin eliminated mites in 100% of dogs by day 60. However, clinical signs of pruritus, erythema, scale, and crusted papules did not diminish concomittantly with resolution of S. scabiei in skin scrapings. The positive‐control products achieved similar results. Therefore, selamectin was safe and effective against sarcoptic mange and ear mites in dogs. Funding: Pfizer Animal Health.     

Clinical and therapeutic studies on mange in horses

At Kafr El-Sheikh province, Egypt, out of 117 examined drafting horses, mites were detected in 20 (17.09%) horses. The recovered mites were 14 Chorioptes, four Psoroptes and two Sarcoptes whereas mites were not detected in four cases clinically showed typical mange lesions. Interestingly, neither the age nor the sex of the examined horses had a clear influence on the prevalence of the infection. Clinical signs observed in mange infested horses were in the form of irregular skin lesions, severe itching and sometimes biting of affected skin areas and decrease feed consumption. The skin lesions mainly start as erythematous area followed by developing of papules and crust formation. Skin scratches as a result of traumatized lesions usually occurred. Hair was lost on the affected parts developing irregular alopecic areas. Distribution of the lesions was varied according to the type of mite. Chorioptic mite was detected in para-anal fold, distal portion of legs and tail lesions, Psoroptic mite was detected in withers, mane, shoulder and flank lesions whereas Sarcoptic mite was isolated mainly from lesions on the head and neck. Complete clinical and parasitological cure for mite infestation were obtained within 2 weeks in both moxidectin and ivermectin treated groups with 100% recovery rate. Our results indicated that moxidectin oral gel is effective and good alternative for the treatment of chorioptic mange in horse to avoid drug resistance that may develop as a result of the intensive use of ivermectin alone for long periods.     

Acaricide treatment prevents adrenocortical hyperplasia as a long-term stress reaction to psoroptic mange in cattle

In cattle, infestation with Psoroptes ovis mites may cause severe dermatitis (psoroptic mange) which compromises the health and welfare of the animals and may lead to significant economic losses. To investigate yet undocumented effects of psoroptic mange mite infestations and how successful therapy promotes animal health, the present study examined alterations of the skin, lymph nodes and adrenal glands of P. ovis infested Fleckvieh (Simmental) bulls treated with either ivermectin long-acting injection (IVM LAI; IVOMEC^® GOLD, Merial; 3.15% ivermectin w/v) or saline (n = 16 each). Approximately 8 weeks subsequent to experimental infestation with P. ovis, the bulls had developed mange and were administered either IVM LAI or saline once at 1 mL/50 kg body weight by subcutaneous injection. Mite counts were conducted in weekly intervals for determination of efficacy of treatment, and following humane euthanasia of the animals 8 weeks after treatment, skin samples from affected (mangy or previously mangy) and unaffected areas, prescapular lymph nodes and adrenal glands were collected for gross and pathohistological examination. In addition, four age-matching, uninfested Simmental bulls were sampled as controls for comparison.No P. ovis mites were detected on any IVM LAI-treated bull after 28 days following treatment whereas saline-treated bulls maintained infestation throughout the study. At sampling (approximately 16 weeks after experimental infestation and 8 weeks following saline or IVM LAI treatment), saline-treated bulls displayed a severe, exsudative dermatitis with significantly increased skin thickness and inflammatory cell infiltration, significantly enlarged, hyperplastic prescapular lymph nodes, as well as significantly increased adrenal gland weights and volumes as compared to P. ovis-infested, IVM LAI-treated bulls and uninfested controls. Quantitative stereological analysis revealed that the adrenal gland enlargement in P. ovis-infested, saline-treated bulls was due to a selective increase of the volume of the zona fasciculata in the adrenal cortex. Compared to uninfested controls and P. ovis-infested, IVM LAI-treated bulls, the number of epithelial cells in the zona fasciculata was significantly increased in P. ovis-infested, saline-treated bulls, while the zona fasciculata cell volumes did not differ between the three groups of cattle. While the single point determination of serum cortisol concentrations did not reveal significant differences between the three groups of cattle at tissue sampling, the hyperplastic growth of the adrenal cortex in the P. ovis-infested, saline-treated bulls provides morphologic evidence that a chronic stress reaction is one consequence of mange mite infestations that can be prevented by efficacious acaricidal treatment.     

Combined moxidectin and environmental therapy do not eliminate Chorioptes bovis infestation in heavily feathered horses

Chorioptes bovis infestation is a common cause of pastern dermatitis in the horse, with a predilection in draft horses and other horses with thick hair ‘feathers’ on the distal limbs. The treatment of this superficial mite is challenging; treatment failure and relapse are common. Furthermore, C. bovis infestation may affect the progression of chronic pastern dermatitis (also known as chronic proliferative pastern dermatitis, chronic progressive lymphoedema and dermatitis verrucosa) in draft horses, manifesting with oedema, lichenification and excessive skin folds that can progress to verruciform lesions. An effective cure for C. bovis infestation would therefore be of great clinical value. In a prospective, double‐blind, placebo‐controlled study, the efficacy of oral moxidectin (0.4 mg/kg body weight) given twice with a 3 week interval in combination with environmental treatment with 4‐chloro‐3‐methylphenol and propoxur was tested in 19 heavily feathered horses with clinical pastern dermatitis and C. bovis infestation. Follow‐up examinations over a period of 180 days revealed significantly more skin crusting in the placebo group than in the treatment group. However, no other differences in clinical signs or the numbers of mites detected were found between the two groups. The results of this study suggest that moxidectin in combination with environmental insecticide treatment as used in this study is ineffective in the treatment of C. bovis in feathered horses.     

A Case of Atypical Psoroptic Mange in a Domestic Rabbit

A female checkered giant cross rabbit (Oryctolagus cuniculus) was presented with skin lesions on the perineal region. The cutaneous lesions extended 2 cm from the vulva and perineal glands. They were moist and erythematous, with abundant greasy yellowish scabs. Skin scrapings from the lesions were mounted in Amman’s chloral-lactophenol on microscope slides and examined at ×10 and ×40 magnification. Numerous mites were observed and identified as Psoroptes cuniculi, a common causal agent of otitis externa in rabbits. The rabbit was treated successfully with ivermectin. This case of psoroptic mange is atypical owing to the perineal location, apparent absence of auricular lesions, and the lack of contagion despite close contact with several other rabbits.     

Efficacy of a novel formulation of metaflumizone plus amitraz for the treatment of sarcoptic mange in dogs

A novel spot-on formulation containing metaflumizone plus amitraz (ProMeris/ProMeris Duo for Dogs, Fort Dodge Animal Health, Overland Park, KS) was evaluated for efficacy against sarcoptic mange mites in naturally infested dogs. Sixteen dogs were allocated to two equal groups and were housed individually. Eight of the dogs were treated topically with metaflumizone plus amitraz at the proposed minimum dose rate (20mg/kg of each of metaflumizone and amitraz, at a dose volume of 0.133ml/kg) on Days 0 and 28. The other eight were treated with metaflumizone plus amitraz at the proposed minimum dose rate on Days 0, 14, 28 and 42. To enumerate Sarcoptes scabiei mites, skin scrapings were taken on each of Days 2, 14, 28, 42 and 56. Clinical signs of mange and the extent of sarcoptic lesions were evaluated on each dog when scrapings were made. Evaluation of the efficacy of the treatment was based on the absence of mites supported by the absence of clinical signs associated with canine sarcoptic mange. Treatment with metaflumizone plus amitraz at the minimum proposed dose rate at monthly (two treatments) or two-weekly (four treatments) intervals resulted in a rapid reduction of mites and improved clinical signs. The overall cure rates at Day 56, based on zero mite counts and/or resolution of clinical signs were 75% and 83% of dogs for the monthly and two-weekly regimens, respectively.     

Sarcoptic mange in three alpacas treated successfully with amitraz

Sarcoptic mange is a serious skin disease in alpacas that can result in high morbidity and even mortality. Three alpacas were presented with sarcoptic mange that had previously failed to respond to repeated topical applications of eprinomectin, and an injection of doramectin. They were moderately to severely pruritic, had extensive lesions of alopecia, erythema, scaling and crusting, and had lost weight. As no drug is currently licensed for the treatment of sarcoptic mange in alpacas in the UK, they were treated with a topical solution of amitraz (50 mL in 10 L) after initial bathing with antibacterial or keratolytic shampoos. The clinical signs completely resolved with no relapse over a 10-month follow-up period. In this small group of alpacas, amitraz was an effective and well-tolerated treatment for sarcoptic mange.